Abstract

Methods of treating a subject with diabetes or Alzheimer's disease with a disclosed islet amyloid polypeptide (IAPP) isoform or peptide are provided. Methods of detecting IAPP isoforms or peptides are also provided.

IPC Classes  ?

• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

Provided herein are a method for identifying targets of cancer drugs and methods of treating cancer using drugs identified herein.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The present disclosure provides pyrazolo[1,5-a]pyrimidine compounds and compositions comprising the same which inhibit IRAK and/or FLT3. The present disclosure further provides methods of using the pyrazolo[1,5-a]pyrimidine compounds to treat a disease or disorder such as a hematopoietic cancer, myelodysplastic syndromes (MDS), or acute myeloid leukemia (AML). Additional embodiments provide disease treatment using combinations of the disclosed IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

A method and system for acquiring free-breathing magnetic resonance (MR) images are provided. The method utilizes a "free" navigator signal acquired by measuring MR signals during or following a slice select ramp down portion of an MRI pulse sequence. After processing the captured navigator signal with sampling-based and temporal filters, the resulting processed navigator signal may include information that correlates strongly with a respiratory cycle of a subject being imaged. Such navigator signal can be used retroactively to process the MRI image data to improve the image quality or resolve respiratory motion. This type of navigator signal can be used to allow fee-breathing of the subject during image acquisition, improving the comfort of the subject, while not significantly increasing the overall image capture time of many common MRI sequence.

IPC Classes  ?

• G01R 33/567 - Image enhancement or correction, e.g. subtraction or averaging techniques gated by physiological signals

Abstract

332333R-unique secondary binding pocket.

IPC Classes  ?

• C07C 235/14 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
• C07C 275/18 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
• C07C 275/24 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
• C07D 207/12 - Oxygen or sulfur atoms
• C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 211/26 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
• C07D 211/40 - Oxygen atoms
• C07D 213/56 - Amides
• C07D 213/64 - One oxygen atom attached in position 2 or 6
• C07D 215/50 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
• C07D 217/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 239/10 - Oxygen or sulfur atoms
• C07D 239/42 - One nitrogen atom
• C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
• C07D 263/20 - Oxygen atoms attached in position 2
• C07D 265/10 - 1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
• C07D 275/04 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
• C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
• A61P 25/18 - Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
• A61P 25/32 - Alcohol-abuse
• A61P 25/36 - Opioid-abuse

Abstract

P. falciparumP. falciparumP. falciparum infection.

IPC Classes  ?

• A61P 33/06 - Antimalarials
• C07K 16/20 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa

Abstract

Disclosed are monoclonal antibodies, antigen binding fragments, and bi-specific antibodies that specifically bind SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies. In some embodiments, the SARS-CoV-2 is the BA.4 or BA.5 variant.

IPC Classes  ?

• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

HHH) antibody libraries by panning the library with an E6- or E7-derived peptide in complex with HLA-A*02:01. Use of the single-domain antibodies for the detection and treatment of HPV-associated cancers and pre-cancerous lesions is also described.

IPC Classes  ?

• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

Abstract

The present disclosure relates to the field of vaccines and binding molecules, as well as preparations and methods of their use in the treatment and/or prevention of disease. Described are vaccines and binding molecules, compositions containing the same, and uses thereof for treating or preventing coronavirus infections, including multivalent mRNA and nanoparticle vaccines.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient

Abstract

Various systems and methods are provided for electrocardiographic radial depth navigation for intracardiac device insertion into a heart. In one example, a method includes acquiring an intracardiac electrogram signal via an electrode of an intracardiac device during insertion of the intracardiac device into a heart muscle or chambers and outputting a radial depth indication with respect to myocardium of the heart based on electronic processing of the intracardiac electrogram signal.

IPC Classes  ?

• A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
• A61B 5/283 - Invasive
• A61B 5/346 - Analysis of electrocardiograms
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

This disclosure provides compositions and methods comprising combinations of IL-15 or an I L-15/IL-15Ra complex with one or more other active agents for the treatment of cancer. This disclosure also provides compositions and methods comprising combinations of IL-15 or an IL-15/I L-15Rct complex fused to IL-12 or a derivative thereof, and with one or more other active agents for the treatment of cancer. In some embodiments, the one or more active agents comprises an activator of PPAR. In some embodiments, the one or more active agents comprises inhibitor of FLT3. In some embodiments, the one or more active agents comprises a chemotherapeutic agent.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides an HIV-1 Env-derived immunogen that simultaneously engages more than one lineage of germline bNAbs specific for different neutralization target sites of the native HIV-1 Env trimer. In certain embodiments, the inventive immunogen comprises a chimeric Env, with binding sites drawn from more than one native Env proteins. These can be used both in the form of full-length/minimally truncated membrane-bound trimers (e.g., expressed from cDNA, mRNA or viral vectors, which also are provided by the present invention, as are cells comprising the immunogen) or, alternatively, in the form of soluble truncated trimers (e.g., SOSIP or IP trimers). Also provided are a pharmaceutical composition comprising the inventive immunogen, nucleic acids encoding the same, and/or cells comprising them, and a method of vaccinating a human patient against HIV using the inventive immunogen and composition.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses

Abstract

Halophthalimides are disclosed. The halophthalimides may inhibit TNF-α activity, TNF-α synthesis, inflammation, inducible nitric oxide synthase, SARS-CoV-2 virus, or any combination thereof. The halophthalimides may be administered to a subject with a traumatic brain injury, an inflammatory disorder, an autoimmune disorder, a neurodegenerative disease, a viral infection, or any combination thereof. The disclosed halophthalimides have a structure according to Formula (I), or a stereoisomer or pharmaceutically acceptable salt, solvate, or hydrate thereof,

IPC Classes  ?

• C07D 209/48 - Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/20 - Hypnotics; Sedatives
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/4035 - Isoindoles, e.g. phthalimide
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone

Abstract

Monoclonal antibodies are antigen binding fragments are disclosed that specifically bind to the underside of influenza A neuraminidase (NA). In some aspects, these antibodies and antigen binding fragments are used for in methods of treating a subject with an influenza A infection, such as an H3N2 infection. In more aspects, these antibodies and antigen binding fragments and bispecific antibodies for detection of an influenza virus in a sample, and for selecting vaccines.

IPC Classes  ?

• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The present disclosure provides a method of treating an inflammatory disease/disorder, acute myeloid leukemia (AML), or myelodysplastic syndrome (MDS) in a subject comprising administering to the subject a compound that inhibits IRAKI and IRAK4. The present disclosure further provides a method of determining a compound that is effective at treating an inflammatory disease/disorder, AML, or MDS.

IPC Classes  ?

• C07D 471/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed system contains two hetero rings
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• C07D 513/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings

Abstract

The present disclosure relates to vaccines, therapeutic antibodies and methods of making such vaccines and antibodies. More specifically, the disclosure relates to methods of immunofocusing an immune response to a protein having both neutralizing epitopes and non-neutralizing epitopes, such that the immune response is preferentially, or completely, directed towards, or away from, a particular portion of the antigen. The disclosure also relates to methods of using the disclosed vaccines and immunofocused proteins to vaccinate an individual and to detect neutralizing antibodies in a sample from an individual.

IPC Classes  ?

• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
• A61P 33/06 - Antimalarials
• C07K 14/445 - Plasmodium
• C07K 16/20 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa

Abstract

Compounds having opioid characteristics are provided that can be used for various therapeutic methods including the treatment of pain and opioid use disorders, and compounds having opioid antagonist properties that can be used to treat opioid overdoses. These compounds include agonists and antagonists having selective activity toward more one or more opioid receptors. Such compounds can be full or partial agonists, or can be antagonists lacking agonist properties toward delta and kappa opioid receptors. The partial agonists can diminish side effects associated with traditional opioid medications, and the antagonists can overcome respiratory depression caused by potent narcotics. Structurally these compounds include constrained piperidines with alkenyl or cyanoalkyl groups, as well as other substituents providing desired properties.

IPC Classes  ?

• A61P 25/36 - Opioid-abuse
• C07D 221/22 - Bridged ring systems

Abstract

Disclosed is a class of kinase inhibitors. Related pharmaceutical compositions and methods of making and using the kinase inhibitors are also disclosed.

IPC Classes  ?

• C07D 473/32 - Nitrogen atom
• C07D 473/00 - Heterocyclic compounds containing purine ring systems
• C07D 487/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings

Abstract

Methods of treating or inhibiting viral infection-induced airway fibrosis in a subject, the method including administering to the subject an effective amount of a composition including one or more direct thrombin inhibitors or one or more serine protease inhibitors or metalloprotease inhibitors are provided. In some examples, the composition is administered to the subject by inhalation. In particular examples, the viral infection-induced airway fibrosis is a coronavirus infection-induced airway fibrosis.

IPC Classes  ?

• A61P 7/02 - Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 31/12 - Antivirals
• A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 38/58 - Protease inhibitors from humans from leeches, e.g. hirudin, eglin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention is directed to methods for treating macular degeneration, atherosclerosis, fatty liver, obesity, and cognitive ability, and more specifically to methods for treating macular degeneration, atherosclerosis, fatty liver, obesity, and cognitive ability using very long chain polyunsaturated fatty acids having 24 to 40 carbon atoms.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/06 - Antihyperlipidemics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/02 - Ophthalmic agents

Abstract

This disclosure generally relates to methods and compositions for eliciting broad and robust immune responses to a protein of interest. The methods employ both DNA and RNA-based vaccines that encode at least a portion of the protein of interest.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

In aspects, the disclosure provides devices and methods for linking omics datasets associated with a reusable single cell or nucleus.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The present disclosure relates to compositions and methods for improving wound healing and tissue regeneration. More specifically, the present disclosure relates to compositions, and methods of using such compositions, that direct the immune response within a wound towards a pro-regenerative response. Such compositions and methods are particularly useful in altering the immune response elicited by medical implants, to avoid scarring and fibrosis at the site of implantation.

IPC Classes  ?

• A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages

Abstract

Disclosed is a method of impeding platinum-based chemotherapeutic induced ototoxicity, and/or other toxicity, the method comprising administering a colony stimulating factor 1 receptor (CSF1R) inhibitor to a subject in an amount sufficient to impede ototoxicity, and/or other toxicity, inducible by a platinum-based chemotherapeutic; and administering the platinum-based chemotherapeutic to the subject. The CSF1R inhibitor can be, for example, pexidartinib. The platinum-based chemotherapeutic can be, for example, cisplatin. Compositions, medicaments, kits, and uses are disclosed related to the same. Further, a method of screening for a compound able to impede a platinum-based chemotherapeutic induced toxicity is disclosed.

IPC Classes  ?

• A61K 31/282 - Platinum compounds
• A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 33/243 - Platinum; Compounds thereof
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61N 5/00 - Radiation therapy
• A61P 27/16 - Otologicals

Abstract

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

IPC Classes  ?

• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

The present invention relates to compositions and methods in the context of mitochondrial transfer. Disclosed herein are methods that enable the efficient transfer of mitochondria from a donor cell to a recipient cell. The mitochondria-augmented cells are useful in the treatment of diseases and disorders, such as cancer. The present invention also relates to the molecular machinery involved in mitochondrial transfer.

IPC Classes  ?

• C12N 5/0786 - Monocytes; Macrophages
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes

Abstract

Monoclonal antibodies that specifically bind CD25, as well as conjugates of the anti-CD25 antibodies, are described. The CD25-specific monoclonal antibodies and conjugates thereof do not block binding of IL- 2 to CD25 and induce little to no antibody -dependent cellular cytotoxicity (ADCC). The anti- CD25 antibodies and conjugates can be used, for example, to target photoimmunotherapy to T regulatory (Treg) cells in tumor beds to enhance the local host immune response to the tumor.

IPC Classes  ?

• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Disclosed are antigen binding antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptide complexes; and methods of using such polypeptide complexes.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/42 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/4738 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/33 - Heterocyclic compounds

Abstract

Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

IPC Classes  ?

• C07D 487/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains two hetero rings
• A61K 31/5025 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Abstract

The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention also provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.

IPC Classes  ?

• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

A method of training an artificial neural network to predict gene expression for a patient having a pathological condition is provided. The method comprises obtaining a set of histopathological images from a database of patients having the pathological condition, collecting from the database a set of gene expression profiles corresponding to the histopathological images, identifying in the set of gene expression profiles a set of considered genes, selecting a training subset of the considered genes comprising genes characterized by similar median gene expression values, and training the neural network to predict a gene expression value of an input histopathological image, using gene expression profiles of the genes in the training subset simultaneously.

IPC Classes  ?

• G16B 25/10 - Gene or protein expression profiling; Expression-ratio estimation or normalisation
• G16B 10/00 - ICT specially adapted for evolutionary bioinformatics, e.g. phylogenetic tree construction or analysis
• G16B 20/40 - Population genetics; Linkage disequilibrium
• G16B 40/20 - Supervised data analysis

Abstract

Compounds and methods for their use in inhibiting bacterial protein synthesis in gram-positive bacteria and treating gram-positive bacterial infections in a subj ect are provided.

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/047 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• A61K 31/01 - Hydrocarbons
• A61K 31/045 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates

Abstract

Compositions and methods for the treatment of a human subject who has had a stroke or myocardial ischemia reperfusion injury, by administering to the subject a pharmaceutical composition including a compound of Formula (I) and/or of Formula (5) or a pharmaceutically acceptable salt and/or formulation thereof. The pharmaceutical composition can be administered in the acute phase of stroke, optionally in combination with a thrombolytic therapeutic or a procedure on the subject involving a clot-removal device.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/5395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
• A61K 31/33 - Heterocyclic compounds

Abstract

An Artificial Intelligence (AI) system for estimating inferior vena cava (IVC) collapsibility and right atrial pressure (RAP) from an echocardiography study in real-time is provided. The system includes an image retrieval network that is configured to receive images from the echocardiography study and perform a quality assessment of the images to generate selected images. The system further includes a region segmentation network to localize and segment the selected images to obtain IVC regions in the selected images. The system further includes an IVC quantification and RAP estimation network to perform a distance calculation to find a diameter in the IVC regions at different spatial and temporal points, allowing a more reliable estimation of RAP values; and the system further includes an open-world active learning system comprising a classification engine and a clustering engine.

IPC Classes  ?

• G06T 7/00 - Image analysis

Abstract

The present disclosure provides compositions, systems, devices, and methods for the delivery of therapeutics. Particularly, the disclosure provides composition, systems, and devices of the delivery of Janus kinase (JAK) inhibitors and uses thereof, such as for inhibiting allograft rejection or treating autoimmune diseases.

IPC Classes  ?

• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 9/51 - Nanocapsules
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

This disclosure concerns antibodies that are computationally designed and engineered to specifically bind to the spike protein of SARS-CoV-2 strains and variants with high affinity. The disclosure also concerns uses of the antibodies for the detection, prophylaxis, and treatment of SARS-CoV-2 infection.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/42 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Compounds for inhibiting the replication of intracellular microorganisms are described. More specifically, the present disclosure provides transbodies comprising a cell-penetrating moiety (CPM) and a binding moiety (BM). The CPM, which may be a cell-penetrating peptide (CPP), allows translocation of the entire transbody into a cell. The BM, which may comprise an antibody, binds a protein from an intracellular microorganism, thereby inhibiting replication of the intracellular microorganism. The disclosed transbodies may be used to inhibit replication of intracellular microorganisms in cells in culture, and/or they may be used to treat individuals infected with an intracellular microorganism.

IPC Classes  ?

• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Abstract

,, are provided, including the antigen Wb5 or fusion proteins including Wb5 linked to a reporter protein or tag. Nucleic acids encoding the Wb5 protein or the fusion proteins, vectors including the nucleic acids, and host cells including the nucleic acids or vectors are also provided. Methods of detection of antibodies to Wb5 in a sample from a subject, including immunoassay methods are also provided.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Engineered SARS-CoV-2 variants having a combination of attenuating modifications, and their use as live-attenuated SARS-CoV-2 vaccines, are described. The recombinant genome of the live-attenuated SARS-CoV-2 encodes a modified spike (S) protein with a deletion of the polybasic site (DPRRA); encodes a modified non-structural protein 1 (Nsp1) with K164A and H165A substitutions; and includes a mutation that prevents expression of open reading frames (ORFs) 6, 7a, 7b and 8. The disclosed live-attenuated SARS-CoV-2 retain the capacity to infect and replicate in mammalian cells. Immunogenic compositions that include a live-attenuated SARS-CoV-2 and methods of eliciting an immune response against SARS-CoV-2 in a subject are also described. Further disclosed are a collection of reverse genetics plasmids that include the complement of the recombinant genome of the live-attenuated SARS-CoV-2 and methods of producing a live-attenuated SARS-CoV-2 using the reverse genetics plasmids.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/20 - Antivirals for DNA viruses

Abstract

E. colilac E. coliE. coliE. coli.

IPC Classes  ?

• C12N 15/72 - Expression systems using regulatory sequences derived from the lac-operon

Abstract

Described herein are constructs, compositions, and methods for eliciting an immune response against CCHFV. In particular, the disclosure relates to self-replicating RNAs expressing encoding at least one heterologous polypeptide comprising an epitope that elicits an immune response against CCHFV. The disclosure also relates to compositions and nanoparticles comprising the disclosed self-replicating RNAs, and the use of such nanoparticles and compositions to elicit an immune response against CCHFV in an individual, thereby protecting the individual from infection with CCHFV.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Provided herein is a nucleic acid-based vaccine for human T-cell leukemia virus type 1 (HTLV-1). In some aspects, the vaccine includes a combination of nucleic acid molecules encoding HTLV-1 gag protein and one or both of Type A HTLV-1 Envelope (Env) and Type C HTLV-1 Env. In some aspects, the vaccine includes a combination of nucleic acid molecules encoding HIV-1 gag protein and one or both of Type A HTLV-1 Envelope (Env) and Type C HTLV-1 Env. When administered to a subject, the Env and Gag proteins are expressed in the host and form HTLV-1 virus-like particles (VLPs) that are secreted from cells within the host and elicit an immune response that inhibits HTLV-1 infection.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• A61P 31/14 - Antivirals for RNA viruses
• A61P 35/00 - Antineoplastic agents
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses

Abstract

Provided is a compound of formula (I) X1-L-X2(I), in which X1is a residue with an affinity for a Proviral Integration site for Moloney murine leukemia virus (PIM) kinase; L is a linker; and X2 is a residue with an affinity for a ubiquitin ligase. Further provided is a method of treating cancer in a mammal comprising administering to the mammal an effective amount of a compound of formula (I), in which the cancer comprises cancer cells that overexpress a PIM kinase relative to non‑cancerous cells of the same tissue type, such as prostate cancer. [formula II]

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 31/5025 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Various systems and methods are provided for cardiac resynchronization therapy. In one example, apparatus for a multi-electrode pacemaker lead, comprises a plurality of ring electrodes distributed along a length of the multi-electrode pacemaker lead, the multi-electrode pacemaker lead configured to be implanted within myocardium of a wall of a ventricle of a heart such that an outer surface defining a circumference of at least one of the plurality of ring electrodes is in direct contact with the myocardium.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

Modified Factor Xa polypeptides having functional activity and reduced affinity for apixaban are provided. Nucleic acids encoding the modified Factor Xa polypeptides and vectors and host cells including the nucleic acids are also provided. Methods of reducing or inhibiting bleeding, such as in a subject being treated with a direct oral anticoagulant are provided.

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 7/02 - Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

Recombinant antibody T cell receptors (AbTCRs) and chimeric signaling receptors (CSRs) engineered to include antigen-binding domains specific for tumor antigen glypican-2 (GPC2) or glypican-3 (GPC3) are described. Immune cells expressing the AbTCRs and CSRs effectively treated GPC2-positive or GPC3-positive tumors in multiple different xenograft models, and were significantly more potent than similarly targeted chimeric antigen receptor (CAR) T cells.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• A61P 35/00 - Antineoplastic agents

Abstract

ApoE mimetic peptides of 8-17 amino acids long including the ApoE receptor binding region or a portion thereof, and one or more covalent linkages joining at least two non-contiguous amino acids of the peptide are provided. Methods of treating dyslipidemic disorders, such as hypertriglyceridemia or hypercholesterolemia, or viral infection using the peptides are also provided.

IPC Classes  ?

• C07K 14/715 - Receptors; Cell surface antigens; Cell surface determinants for interferons
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 3/06 - Antihyperlipidemics
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

Fibrotic diagnostic systems, subsystems, and components thereof are provided. A fibrotic diagnostic system can comprise a microfluidic device. The fibrotic diagnostic system can be preloaded with one or more components. For example, the fibrotic diagnostic system can comprise the one or more reagents and a target object, for example a tissue, or a medical device, or both intended for implantation. The fibrotic diagnostic system can comprise one or more additional components and subsystems, for example, a detector comprising a sensor configured to detect fibrosis of the target object, a thermal subsystem, a fluidic subsystem, a processor, or a user interface, or any combination thereof. Kits comprising one or more components of a fibrotic diagnostic system are provided. Screening methods for identifying therapeutics are provided that utilize a fibrotic diagnostic system or component thereof are provided. Non-transitory computer-readable media storing a program are further provided.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

An imaging system and method includes a microscope for observing a sample. A light source is arranged to generate light along an optical path of the microscope. A lens array is positioned in the optical path of the microscope, the lens array having a plurality of lenses each with a lens optical axis, the lens optical axes positioned to each capture a separate field of view of the sample. At least one detector is configured to detect the separate fields of view from the lenses. The imaging system is configured to mosaic the detected separate fields of view from each lens to generate an image of the sample.

IPC Classes  ?

• G02B 21/02 - Objectives
• G02B 21/00 - Microscopes
• G02B 3/00 - Simple or compound lenses

Abstract

The disclosure provides recombinant polypeptides that specifically bind to an envelope epitope of HERV-K HML-2, wherein such engineered polypeptides may be single-domain antibodies or immunoglobulin variable domains. The disclosure also provides CAR comprising such recombinant polypeptides. The disclosure further provides nucleic acid molecules that encode such recombinant polypeptides or CARs, and methods of making such recombinant polypeptides or CARs. The disclosure further provides pharmaceutical compositions that comprise such recombinant polypeptides or CARs, and methods of treatment using such recombinant polypeptides or CARs.

IPC Classes  ?

• A61K 39/42 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/12 - Antivirals
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

Abstract

In aspects, the disclosure provides genetically engineered cells, uses of the cells, and methods of making the cells.

IPC Classes  ?

• C12N 5/0789 - Stem cells; Multipotent progenitor cells
• C12N 5/0775 - Mesenchymal stem cells; Adipose-tissue derived stem cells

Abstract

A method of multiplexing Hcy and/or Cys in a first-tier screening assay includes: contacting a blood sample with a reducing agent optionally in the presence of a solvent to convert at least one of a Hcy dimer, a Hcy-protein complex, a Cys dimer different from the homocysteine dimer, or a Cys-protein complex in the blood sample to a Hcy and/or Cys monomer thereby forming a monomer sample; reacting the Hcy and/or Cys monomer in the monomer sample with a thiol derivatizing agent to form a thiol derivatized sample comprising a thiol derivatized Hcy and/or Cys monomer; and optionally converting a carboxylic acid or a carboxylate group in the thiol derivatized Hcy and/or Cys monomer to an ester, forming a thiol-and-ester derivatized sample comprising a thiol-and-ester derivatized Hcy and/or Cys monomer. The method can be used to determine a level of tHcy, a level of tCys, and/or a level of CysT in a blood sample, and screen for CBS deficiency, HCU, or hyperhomocysteinemia.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

A bispecific monoclonal antibody that specifically binds two distinct epitopes of the Ebola virus (EBOV) glycoprotein (GP) is described. The bispecific antibody is comprised of the antigen binding domains of GP-specific monoclonal antibodies mAb114 and S1-4-A09 ("A09"). The EBOV GP bispecific monoclonal antibody (mAb114xA09 or BiSp107) exhibits synergistic neutralization of pseudotyped virus expressing EBOV GP compared with the neutralization capacity of the combination of the individual parental antibodies. Methods for pre- and post-exposure prophylaxis and treatment are described.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Disclosed is a sterile MRI probe infusion device for preparing and administering a hyperpolarized MRI probe to a patient in need thereof. The device includes one or more reaction chambers, where a hyperpolarized MRI probe is prepared, separated from the reaction mixture, concentrated, and a solution of suitable concentration for administration to a patient is prepared. Also disclosed is a method of preparing and administering a hyperpolarized MRI probe by the use of the device to a patient in need thereof for diagnosing stages of a disease or an adverse condition or monitoring progress of a treatment of the patient having a disease or an adverse condition.

IPC Classes  ?

• G01R 33/28 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance - Details of apparatus provided for in groups
• A61K 49/10 - Organic compounds

Abstract

mqq] or a salt thereof. Also disclosed is a method of preparing a hyperpolarized substrate comprising a ½ spin nucleus or nuclei using the perfluorinated SABRE catalysts, and isolating the resulting hyperpolarized substrate for administration to an animal. Further disclosed is a method of imaging a tissue of an animal suspected of having a disease or condition.

IPC Classes  ?

• B01J 31/22 - Organic complexes

Abstract

123456123456 78978910111213141510111213141515 is any amino acid, wherein the isolated peptide is at most 75 amino acids in length. Molecules including these isolated polypeptides are disclosed, as well as nucleic acid molecules and vectors encoding these polypeptides. Pharmaceutical compositions including the polypeptides, molecules, nucleic acids and vectors are of use for increasing vascular nitric oxide bioavailability and/or inhibiting vasoconstriction in a subject.

IPC Classes  ?

• A61P 9/08 - Vasodilators for multiple indications
• C07K 14/805 - Haemoglobins; Myoglobins
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Methods of synthesizing (R)-N-(4-(4-(3-chloro-5-ethyl-2- methoxyphenyl) piperazin-l-yl)-3-hydroxybutyl)-l H-indole-2- carboxamide (compound 8) are described as well as intermediate compounds of formulae 5-7, 9 and 14 used in said methods.

IPC Classes  ?

• C07D 295/096 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• C07C 271/16 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
• C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
• C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Abstract

Compositions and methods are provided to enrich for DNA corresponding to a genome of interest, e.g. by species, clade, or strain of origin, from a mixed population of nucleic acid sequences. The methods may further comprise identification of the genomic sequences of interest, e.g. identifying the species, clade, strain, etc. of origin.

IPC Classes  ?

• C12Q 1/10 - Enterobacteria
• C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
• G01N 27/447 - Systems using electrophoresis

Abstract

Bispecific antibodies that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these bispecific antibodies, vectors and host cells are also provided. In addition, the use of these bispecific antibodies, nucleic acid molecules, and vectors to prevent and/or treat an HIV-1 infection is disclosed.

IPC Classes  ?

• A61P 31/18 - Antivirals for RNA viruses for HIV
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

Antibodies and antigen binding fragments that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

IPC Classes  ?

• A61P 31/18 - Antivirals for RNA viruses for HIV
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

Methods for treating diabetic retinopathy and age-related macular degeneration (AMD), as well as pharmaceutical compositions relevant thereto are disclosed.

IPC Classes  ?

• A61P 27/02 - Ophthalmic agents
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

Abstract

Disclosed are compounds of the formula (I): wherein R1-R5122 are as defined in the specification, pharmaceutical salts thereof and stereoisomers thereof, and pharmaceutical compositions containing one or more of these compounds, salts, or stereoisomers thereof. Also disclosed is a method of treating a having a condition selected from the group consisting of chronic neuropathic pain, heart disease, suppressed immunity, and a disease of the liver, psoriasis, and cancer by administering to the subject having such a condition an effective amount of the compound or pharmaceutical composition.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 17/06 - Antipsoriatics
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Abstract

Immunogens comprising a soluble HIV-1 Env ectodomain trimer stabilized in a prefusion closed conformation and comprising modifications to introduce N-linked glycan sequons at the membrane-proximal base of the trimer, as well as methods of their use and production are disclosed. In several implementations, the immunogen can be used to elicit an immune response to HIV-1 in a subject.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• C07K 14/16 - HIV-1
• C12N 15/49 - Lentiviridae, e.g. immunodeficiency viruses such as HIV, visna-maedi virus, equine infectious anaemia virus
• A61P 31/12 - Antivirals

Abstract

The application relates to compounds of the general Formula (I) which act as cannabinoid receptor modulators useful for the treatment of complications arising from metabolic, inflammatory and fibrotic disorders.

IPC Classes  ?

• C07D 237/04 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 35/00 - Antineoplastic agents
• A61K 31/50 - Pyridazines; Hydrogenated pyridazines
• A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide

Abstract

Antibodies and antigen-binding fragments thereof are provided that bind beta-1,6-poly-N-acetyl glucosamine (PNAG) that has been deacetylated in whole or part (dPNAG). Compositions and kits comprising these antibodies and antigen-binding fragment thereof are also provided. Such compositions can include, for example, diagnostic and therapeutic compositions. Methods of using these antibodies and antigen-binding fragments thereof are further provided. Such methods can include, for example, methods for preventing, diagnosing, and treating bacterial infections and associated biofilms characterized by PNAG and dPNAG.

IPC Classes  ?

• A61P 31/04 - Antibacterial agents
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Therapeutic agents, compositions, and methods are described for use in the treatment of acute or chronic pain, neuroinflammation, or conditions characterized by acute or chronic pain or neuroinflammation. The therapeutic agents comprise a synthetic amphipathic helical peptide capable of acting as a mimetic of apoA-I protein.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• C07K 14/775 - Apolipopeptides
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/10 - Peptides having 12 to 20 amino acids

Abstract

A bat restraining device includes a capsule, a plunger, and a base. The capsule includes top and bottom shells, at least one of which includes a longitudinally extending concave inner surface forming a cavity between the top and bottom shells. The top and bottom shells are removably coupled together, spaced apart along at least a portion of their length. At least a portion of a proximal end of the plunger is configured and disposed to slide in a longitudinal direction in a proximal end of the cavity formed between the top and bottom shells. One of the bottom shell and the plunger is secured with the base, while the other of the bottom shell and the plunger is movable in the longitudinal direction relative to the base.

IPC Classes  ?

• A61D 3/00 - Appliances for supporting or fettering animals for operative purposes 
• A01K 1/06 - Devices for fastening animals, e.g. halters, toggles, neck-bars or chain fastenings

Abstract

Optimized chimeric antigen receptors (CARs) targeting glypican-2 (GPC2) and having a CD28 hinge region and a CD28 transmembrane domain are described. The antigen-binding domain of the disclosed CARs is derived from GPC2-specific antibody CT3 or humanized versions thereof. The optimized CARs also include an intracellular co-stimulatory domain and an intracellular signaling domain. Immune cells or induced pluripotent stem cells expressing the optimized CARs can be used to treat GPC2-positive solid tumors, such as neuroblastoma.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 14/725 - T-cell receptors

Abstract

Disclosed is a compound of formula (I), in which R1, R2, R3, R4, R5, X1, X2, X3, X4, and X5 are described herein. The small molecule compounds of formula (I) activate the functional activity of relaxin family peptide receptor 2 (RXFP2), thereby providing therapeutic treatments for a variety of disorders, such as a bone disorder, hypogonadism, cryptorchidism, polycystic ovary syndrome, cancer, infertility, or an ocular wound.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 35/00 - Antineoplastic agents
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam

Abstract

Methods are disclosed herein for treating a cancer in a subject. Embodiments of the methods include administering to the subject a therapeutically effective amount of a combination therapy comprising a TLR4 agonist (such as HMGN1), a TLR2/6 agonist (such as FSL-1), and a checkpoint inhibitor. Optionally, the combination therapy administered to the subject can include a STING agonist (such as cGAMP or c-di-GMP). In some embodiments, the checkpoint inhibitor is a PD-L1 inhibitor, a PD-1 inhibitor, a TNFR-2 inhibitor, or a CTLA-4 inhibitor. In some embodiments, the cancer is a colorectal cancer, a kidney cancer, or melanoma.

IPC Classes  ?

• A61K 38/18 - Growth factors; Growth regulators
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed are monoclonal antibodies and antigen binding fragments that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection. In addition, disclosed are methods for detecting a coronavirus in a biological sample, using the disclosed antibodies.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

Some embodiments of the disclosure include disclosed compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the disclosed compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the disclosed IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

IPC Classes  ?

• A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
• A61K 31/44 - Non-condensed pyridines; Hydrogenated derivatives thereof
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/33 - Heterocyclic compounds

Abstract

Ultrasound measurement devices can include a chamber configured to retain an ultrasound detection fluid, wherein the ultrasound detection fluid is configured to absorb an ultrasound beam and to reduce a temperature variation across the chamber during heating by the ultrasound beam, and an acoustic power meter including at least one temperature sensor coupled to the chamber, wherein the temperature sensor is operable to sense a temperature change of the ultrasound detection fluid in response to the heating by the ultrasound beam and the acoustic power meter is configured to estimate a power of the ultrasound beam based on the temperature change.

IPC Classes  ?

• G01H 3/10 - Amplitude; Power

Abstract

11, Xa, Xb, Xc, and Xd are as described in the specification. Further disclosed is an isotopic mixture of a compound of Formula (I), as well as a pharmaceutical composition containing a hyperpolarized compound of Formula (I). Also disclosed is a method of diagnosing or monitoring a patient suffering from cancer, the method including administering a pharmaceutical composition comprising an effective amount of a hyperpolarized ketoglutarate compound or a pharmaceutically acceptable salt thereof, and measuring the hyperpolarization of a compound of interest in the patient. Further disclosed is a method of preparing hyperpolarized ketoglutarate compounds for use in the above methods.

IPC Classes  ?

• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• A61K 51/04 - Organic compounds
• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
• C07D 265/30 - 1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
• C07C 59/347 - Saturated compounds having more than one carboxyl group containing keto groups
• C07C 69/716 - Esters of keto-carboxylic acids

Abstract

Gingerenone A prodrug compounds have a structure according to Formula I, or a pharmaceutically acceptable salt thereof wherein one of R1and R2is H or -C(O)-R and the other of R1and R2is -C(O)-R. Each R independently is RAor, where RA182222 alkenyl, and RB is an amino acid side chain. The compounds are useful for inhibiting or eliminating senescence. The compounds may be administered to a subject having a senescence-associated disease or disorder, neuroinflammation, pain, and/or an amino acid deficiency.

IPC Classes  ?

• C07C 69/587 - Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
• C07C 201/00 - Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
• A61K 31/125 - Camphor; Nuclear substituted derivatives thereof
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

Provided herein are methods of determining loss of heterozygosity in human leukocyte antigen in liquid biopsies and applications thereof in cancer treatment.

IPC Classes  ?

• G16B 20/10 - Ploidy or copy number detection
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

Nipah henipavirus Nipah henipavirus (NiV) virus replicon particles (VRPs) are disclosed herein. These VRPs can be used to induce an immune response to NiV or Hendra virus (HeV). In some embodiments, the NiV VRP include a recombinant NiV genome, wherein the recombinant NiV genome comprises a deletion in a nucleic acid sequence encoding the F protein such that functional mature F protein cannot be produced from the recombinant NiV genome; and a NiV envelope comprising F, G and M proteins of NiV. These VRP can infect human cells but cannot produce NiV particles from the infected human cells. Immunogenic compositions including the NiV VRP are also disclosed. In some embodiments, methods are disclosed for producing NiV VRP. The use of the disclosed NiV VRP to induce an immune response is also disclosed.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Abstract

The disclosure provides various embodiments of systems to facilitate the cutting of myocardial tissue structures percutaneously.

IPC Classes  ?

• A61B 18/08 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by means of electrically-heated probes
• A61M 25/09 - Guide wires
• A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets
• A61B 17/32 - Surgical cutting instruments

Abstract

Estradiol compounds and methods of using the same for treating diseases and conditions including depressive disorder, an anxiety disorder, post-traumatic stress disorder (PTSD), drug addiction, schizophrenia, Alzheimer's dementia, Parkinson's disease, stroke, traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), complex regional pain syndrome (CRPS), chronic pain, neuropathic pain, anhedonia, fatigue, andropause-induced symptoms, and orchiectomy-induced symptoms are provided.

IPC Classes  ?

• C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
• A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/24 - Antidepressants

Abstract

Provided herein are methods of predicting the response of a subject's cancer to one or more cancer treatments by using gene expression data obtained from single cells of the cancer, and methods of treating the cancer.

IPC Classes  ?

• G16B 25/10 - Gene or protein expression profiling; Expression-ratio estimation or normalisation
• G16B 5/10 - Boolean models
• G16B 40/20 - Supervised data analysis
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Polynucleotide expression cassettes comprising synthetic polynucleotides encoding human propionyl-CoA carboxylase alpha (synPCCA) are described herein. Related recombinant expression vectors, recombinant adeno-associated viruses (rAAVs), and compositions are also described. Also described are methods of treating a disease or condition mediated by propionyl-CoA carboxylase, comprising administering to a subject in need thereof a therapeutic amount of any of the polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions.

IPC Classes  ?

• C12N 15/863 - Poxviral vectors, e.g. vaccinia virus
• A61P 3/00 - Drugs for disorders of the metabolism
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Disclosed are methods of treating or preventing cancer in a mammal, the method comprising: (a) isolating T cells from a tumor sample from the mammal, wherein the isolated T cells are one or both of exhausted and differentiated, and the isolated T cells have antigenic specificity for a tumor-specific antigen expressed by the tumor sample from the mammal, wherein the tumor-specific antigen is a tumor-specific neoantigen or an antigen with a tumor-specific driver mutation; and optionally expanding the numbers of isolated, tumor antigen-specific T cells; and (b) administering to the mammal (i) the isolated T cells of (a) and (ii) a vaccine which specifically stimulates an immune response against the tumor-specific antigen for which the isolated T cells have antigenic specificity.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The disclosure provides methods for carrying out Real Time Cellular Thermal Shift Assays (RT-CETSA). Also provided are molecular constructs and protein constructs for use in such assays and devices suitable for carrying out such assays. Also provided are non-parametric methods for analyzing data from RT-CETSA and other biological target engagement assays.

IPC Classes  ?

• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 33/542 - Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Abstract

Myotis LucifugusMyotis Lucifugus DNA transposon involving modification both its transposase and transposon LE and RE ends by truncations leading to hyperactivity.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

Disclosed herein are formulation embodiments comprising levonorgestrel butanoate ("LNGB") particles having particle sizes that facilitate administering a higher concentration of LNGB at lower volumes. The disclosed formulation embodiments exhibit long-lasting contraceptive effects and can be administered subcutaneously, which lends to their utility in acting as self-administrable contraceptive formulations that do not result in side effects associated with other contraceptive agents.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/10 - Dispersions; Emulsions
• A61K 9/16 - Agglomerates; Granulates; Microbeadlets
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/38 - Cellulose; Derivatives thereof

Abstract

582-598 582-598 (IPNGYLVLDLSMQEALS) (SEQ ID NO: 1) are disclosed. Anti-mesothelin binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides, proteins, and CARs are disclosed. Methods of reducing mesothelin shed from cell membranes, methods of detecting the presence of cancer, and methods of treating or preventing cancer are also disclosed.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 14/825 - Metallothioneins
• A61P 35/00 - Antineoplastic agents

Abstract

gene Dgene Egene E, in the lambda genome, and wherein expression of the fusion protein results in the head of the bacteriophage λ comprising the fusion protein. Host bacterial cells also disclosed herein that are infected with the bacteriophage λ. In addition, immunogenic compositions are disclosed that include an effective amount of the bacteriophage λ. Methods also are disclosed for inducing an immune response to the heterologous antigen in a subject. Furthermore, methods are disclosed for preparing these bacteriophage λ.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
• A61K 39/12 - Viral antigens
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof

Abstract

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to sulfur- and selenium-containing compounds that act as agonists and/or antagonists of cannabinoid receptors, methods of making same, pharmaceutical compositions comprising the same, and methods of treating metabolic disorders, psychiatric disorders, neurological disorders, pain disorders, gastrointestinal disorders, cancers, inflammation-related disorders, substance abuse associated pathologies, and other conditions using the same.

IPC Classes  ?

• C07D 231/06 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings

Abstract

Antisense oligonucleotides (ASOs) are provided which are capable of modulating splicing by preventing inclusion of an UNC13A cryptic exon into an UNC13A mature mRNA. Such ASOs may be used as a medicament, for example, to treat neurodegenerative disorders, particularly those associated with TDP-43 pathology.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with valine. The TCRs may recognize G12V RAS presented by HLA-A3. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

IPC Classes  ?

• C07K 14/725 - T-cell receptors

Abstract

The present disclosure provides a human metapneumovirus (hMPV) vaccine comprising an hMPV F protein antigen, and methods of eliciting an immune response by administering said vaccine.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses

Abstract

The present disclosure relates generally to compositions and methods for inhibiting dipeptide repeat protein (DPR)-ribosomal RNA (rRNA) interaction. In particular, the present technology relates to administering a therapeutically effective amount of one or more compositions that inhibit DPR-rRNA interaction to a subject diagnosed with, or at risk for DPR-associated pathologies, e.g., amyotrophic lateral sclerosis or frontotemporal dementia.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Disclosed herein are methods directed to treating bile duct cancers, including cholangiocarcinoma, with tivozanib. The bile duct cancers may be advanced, metastatic or recurrent. The invention also includes methods of identifying subjects having bile duct cancers that express exportin 7 (XPO7) or Ste-20 like kinase (SLK) and treating them with tivozanib.

IPC Classes  ?

• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

Coronavirus spike protein, for example, SARS-CoV-2 spike (S) protein, expressed by an avian paramyxovirus type 3 (APMV3) as a vaccine vector for prevention and treatment against infection, such as SARS-CoV-2.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Abstract

Disclosed are methods to determine a homeostatic steady-state of a biological entity. Also disclosed are methods to quantify an exchange rate between at least two compartments in a biological system, to use Nuclear Magnetic Resonance (NMR) to characterize physiological water transport, and methods for non-invasively measuring transmembrane exchange rates of endogenous water in a biological system under steady-state or non-steady-state conditions in near-real time.

IPC Classes  ?

• G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
• G01R 33/465 - NMR spectroscopy applied to biological material, e.g. in vitro testing
• G01R 33/38 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field
• G01R 33/44 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
• G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography

Abstract

Provided herein are nucleic acid molecules encoding a SARS-CoV-2 S ectodomain – HBsAg fusion protein. When expressed in mammalian cells (for example, by administration to a mammalian subject), the fusion protein self-assembles to form a HBsAg protein nanoparticle with SARS-CoV-2 S ectodomain trimers extending radially outward from an outer surface of the HBsAg protein nanoparticle. Thus, in several aspects, the disclosed nucleic acid molecule can be used to generate an immune response to SARS-CoV-2 in a subject.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Optimized chimeric antigen receptors (CARs) targeting glypican-3 (GPC3) and having a 12-amino acid hinge region derived from human IgG4 are described. The optimized CARs also include a transmembrane domain from either CD8 or CD28, an intracellular co-stimulatory domain and an intracellular signaling domain. Immune cells or induced pluripotent stem cells expressing the optimized CARs can be used to treat GPC3-positive solid tumors.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

Various embodiments for a three-dimensional structured illumination microscopy system having a mirror positioned in diametric opposition to the objective for producing additional illumination components by a fourth beam generated by the mirror and a computational means for accomplishing the same are disclosed herein.

IPC Classes  ?

• G02B 21/06 - Means for illuminating specimen
• G02B 21/14 - Condensers affording illumination for phase-contrast observation
• G01N 21/64 - Fluorescence; Phosphorescence

Abstract

P. falciparumP. falciparumP. falciparum infection.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 33/06 - Antimalarials
• C07K 16/20 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
• A01K 67/027 - New breeds of vertebrates
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells